TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protara Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.33+0.01 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $142.15M
- P/E (TTM)
- –
- Dividend yield
- –
Protara Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Market Cap | $137.69M | $166.30M |
| Enterprise Value | -$4.80M | $88.19M |
| PB Ratio | 0.85 | 2.03 |
| P/TBV Ratio | 0.85 | 2.29 |
Income (trailing twelve months)
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$76.79M | -$21.40M |
| Net Income | -$70.02M | -$22.46M |
| EBITDA | -$76.79M | -$16.91M |
| EPS (Diluted) | -$1.36 | -$0.83 |
Returns
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -45.8% | -53.2% |
| Return on Assets (ROA) | -42.0% | -40.9% |
| Return on Invested Capital (ROIC) | -301.2% | -32.4% |
| Return on Capital Employed (ROCE) | -47.2% | -38.1% |
Balance sheet
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $142.49M | $61.43M |
| Net Cash (Debt) | $142.49M | $15.35M |
| Net Cash Per Share | $2.41 | $0.66 |
| Equity (Book Value) | $161.31M | $49.09M |
| Book Value Per Share | $2.73 | $1.37 |
| Tangible Book Value | $161.31M | $23.52M |
| Working Capital | $132.83M | $76.81M |
Financial position
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.97 | 3.34 |
| Quick Ratio | 10.70 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$66.13M | -$12.35M |
Efficiency
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.37M | -$703.34K |
| Employee Count | 51 | 74 |
Dividends and yields
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -50.8% | -23.3% |
Shares
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 59,095,500 | 58,127,000 |
| Shares Change (YoY) | 56.0% | 10.9% |
| Shares Change (QoQ) | 7.32% | 0.54% |
| Float | 57,398,300 | 49,136,700 |
| Shares Held by Insiders | 2.87% | 11.6% |
| Shares Held by Institutions | 78.1% | 59.4% |
Scores
| Measure | Protara Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.34 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Protara Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.